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History of amendments 
 
 Details of amendments 
Version 1. Date: 20/12/18 This document has been adapted from the ‘Detailed Research Plan’ 
(version 2, date: 10-09-18) submitted to the HTA as part of the funding 
application process. The Detailed Research Plan has been adapted in 
the following ways to create this protocol:  
• Incorporated the reference list, flow diagram, plain English 
summary, and additional details on public and patient 
involvement from the funding application form, so all information 
is in one document.  
• Minor updates to formatting/layout (e.g. table of contents, title 
page) and wording to enhance clarity.  
• Additional sections have been added to include a signature 
page, roles of the funder, sponsor, and committees, in line with 
HRA templates. 
Version 2. Date: 01/05/2019 This protocol has been updated following a discussion with our Advisory 
Board on 20th February 2019. These changes were decided upon prior 
to selection of included studies or any data collection.  
 
• PROSPERO Registration number has been incorporated.  
• Further detail has been incorporated to elaborate on our plan 
for the Summary of Findings Tables. 
• We have ordered the priority of our secondary outcomes to 
align with our plan for the Summary of Findings Tables. 
• Minor changes have been made to wording to improve clarity 
of content. 
• Updated search sources to include a wider breadth of trial 
registration sources and removal of one conference 
proceedings because the conference has not been re-run since 
it was last searched in the scoping review. 
• The economic analysis section has been further clarified and 
elaborated upon, with some minor amendments to approach. 
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Draft copies of publications need to be sent to the funder at the same time as submission for 
publication or at least 28 days before the date intended for publication, whichever is earlier. The 
sponsor will provide a draft final report of the research within 14 days of the completion date of the 
project, for which the funder will arrange external peer review. The sponsor will respond to the peer 
review comments within four weeks of receiving them. If the sponsor has not produced a report which 
satisfies the funder within one year of the end of the research period, the funder may prepare and 
publish, or arrange for the preparation and publications of such a report. 
 
Roles and responsibilities of the Advisory Board and Public and Patient Involvement group 
The Advisory Board is comprised of all study collaborators, co-applicants, and the Senior Research 
Associate (Lambert Felix; LF), and is chaired by the Chief Investigator (Amy Drahota; AD). The role 
of the Advisory Board is to provide overall supervision for the project on behalf of the Project Sponsor 
and Project Funder and to ensure that the project is conducted to the rigorous standards set out in 
the Health Research Authority’s “UK Policy Framework for Health and Social Care Research” that 
are applicable to systematic reviews, and “The Concordat to support Research Integrity”.  
 
The day-to-day management of the project is the responsibility of the Chief Investigator (AD), with 
the assistance of the core research team (LF, KFS, BK, CL, OO, JR). The main features of the 
Advisory Board are as follows:  
• To provide advice to the funder, sponsor, and Chief Investigator on all appropriate aspects 
of the project;  
• To concentrate on progress of the project, adherence to the protocol, and the consideration 
of new information of relevance to the research question;  
• To agree proposals for substantial protocol amendments and provide advice to the sponsor 
and funder regarding approvals of such amendments;  
• To provide advice to the investigators on all aspects of the project; 
• To support impact and dissemination activities to facilitate the uptake of the study findings 
into practice. 
The Public Involvement Group will be integral to assuring the transparency and fairness of 
judgements made throughout the review process, helping to prioritise outcomes and how the findings 
are set out, improving the clarity and the appropriate level of comprehensiveness of review outputs, 
as well as helping make the findings accessible. Public Involvement members are to expect an 
appropriate level of training and information to be provided to them to enable them to fulfil their roles. 
The Chief Investigator, with the support of the Senior Research Associate, will be responsible for the 
provision of training and information. The main roles of the Public Involvement Group will be: 
• To advise on the clarity and comprehensiveness of the protocol and study outputs; 
• To monitor and provide independent judgement on the fairness, transparency, and 
consistency of risk of bias and quality assessments made by the research team; 
• To inform the design of the Summary of Findings Tables, with particular emphasis on 
ensuring the clarity of information provided, importance granted to different outcomes, and 
appropriate ordering of information; 
• To help in the design and production of the patient experience video study output; 
• To feed into and actively participate with the Advisory Board. 
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1. Plain English Summary 
 
Aims of the research: We aim to summarise what is known about shock-absorbing flooring in 
hospitals and care homes in terms of reducing injuries from falls. We want to help health 
organizations decide whether or not to invest in using shock-absorbing floors. We will establish if 
shock-absorbing flooring can: (1) reduce injuries from falls; (2) increase the chances of older people  
falling over; and (3) lead to injuries in staff who may find it harder to move equipment across a softer 
floor. We will also summarise any research on the costs and savings of shock-absorbing floors. 
Finally, we will look at any practical issues people have had when installing the new floors, and 
explore the experiences and attitudes of people who have used the floors (staff, residents/patients, 
and visitors). 
 
Background to the research: Falls and fall-related injuries are a major problem in hospitals and 
care homes. Older people are more at risk of falling, and more at risk of injuring themselves if they 
do fall. Injuries from falls can lead to loss of independence and mobility, shorter lives, and lower 
quality lives. Shock-absorbing flooring is one potential solution to help reduce the impact of a fall. 
Researchers from different countries have been studying the use of shock-absorbing floors in 
hospitals and care homes, but nobody has brought all of these studies together to summarise their 
findings in a systematic way. 
 
Design and methods used: We will carry out a thorough systematic search to identify all the studies 
we can find that have looked at shock-absorbing flooring use in hospitals and care homes. We will 
assess these studies for quality, and gather data on what they did, who they involved, and what they 
found. We will summarise the information we find, to make it more easily understood. Where 
appropriate, we will combine the data from different studies to produce an overall result. We will 
explore the differences between studies, to help us understand which factors might influence 
whether shock-absorbing flooring works, and to determine how trustworthy the findings are. We will 
use the findings from studies included in the review to produce recommendations that can guide 
end-users of the review. 
 
Patient and public involvement: Our patient and public members will be involved throughout the 
project. They will help make sure our findings are easy to understand, and include all the important 
information. They will check the judgements we make about the quality of the research we find, to 
make sure we are being fair and clear. They will be involved in meetings to help guide us and make 
decisions. They will help us make a short video, which explains the findings of our research through 
patient experiences. 
 
Dissemination: We will share our findings in different ways to suit different people. We will publish 
our report in an academic journal, with universal free access. We will present our findings at two 
conferences (one in England and one abroad), which have a focus on caring for older people. We 
will also present our results online in the form of a webinar. We will hold a half-day workshop, to 
which we will invite people who may find our review useful. We will produce short reports to give to 
people who make decisions about which flooring to use in hospitals and care homes. Finally, we will 
make a short online video which tells the findings of the review through the views and stories of 
patients as many people like to make decisions when they hear patients’ or residents' views. 
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2. Summary of Research (abstract)  
Research question: What is the clinical and cost-effectiveness of shock-absorbing flooring for fall-
related injury prevention in older adults in care settings? 
Background: Falls in hospitals and care homes are a major issue of international concern. Inpatient 
falls are the most commonly reported safety incident in the NHS, costing the NHS £630 million a 
year. Injurious falls are particularly life-limiting and costly. The urgency of this issue is increasing with 
the complex health and care needs of our ageing population. There is a growing body of evidence 
on shock-absorbing flooring for fall-related injury prevention (13 clinical effectiveness studies, 7 
qualitative studies, and 12 economic records that we are aware of), however no systematic review 
exists to inform practice. 
Aims and objectives: We aim to systematically review the evidence on shock-absorbing flooring 
use in care settings for fall-related injury prevention. Specifically we will: 
1. Assess the benefits (fall-related injury prevention) and risks (falls; staff injuries) of different 
flooring systems. 
2. Assess the extent to which these benefits and harms may be modified by different study/setting, 
intervention, or participant characteristics. 
3. Critically appraise and summarise evidence on the resource use, costs and cost-effectiveness 
of shock-absorbing flooring compared with standard flooring. 
4. Summarise findings on the implementation of flooring interventions.  
5. Summarise the views and experiences of shock-absorbing flooring use, of patients/residents, 
staff, and visitors.  
6. Identify gaps in the evidence. 
Methods: Our project will systematically identify, appraise, and summarise studies investigating the 
clinical and economic effectiveness, and experiences of shock-absorbing flooring in hospitals and 
care homes. Our search will build on an extensive search conducted by a scoping review1 (inception 
to May 2016). We will search six databases (May 2016 – present), clinical trial registries, grey 
literature sources, and sources for economic evidence. We will screen reference lists, conduct 
forward citation searches, and liaise with study researchers. We will evaluate the influence of floors 
on fall-related injuries, falls, and staff work-related injuries, consider economic and qualitative 
evidence, and implementation factors. Randomised and non-randomised studies will be included 
and summarised separately. We will consider risk of bias using the updated Cochrane Risk of Bias 
2.0 tool2 and ROBINS-I tool3. We will assess heterogeneity and explore potential effect modifiers via 
subgroup analyses (study type, setting, acuity of care, intervention type) and sensitivity analyses 
(risk of bias, analysis methods). Where appropriate we will combine studies through meta-analysis. 
The quality of outcomes will be evaluated using the GRADE approach4, and reported using Summary 
of Findings Tables5. 
Timelines for delivery: 14 months. 
Anticipated impact and dissemination: We will disseminate the findings via a range of outputs to 
suit different knowledge users. We will publish in a peer reviewed journal, give presentations (at 
national and international conferences, and webinar), host a stakeholder symposium, produce 
Knowledge-to-Action reports, and create a short video of the review findings via patient experiences. 
We will engage relevant stakeholders from different organisational levels throughout the project to 
facilitate uptake of the findings in practice and guidelines. 
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3. Background and Rationale  
This research aligns with the ‘Complex health and care needs of older people’ priority NIHR theme, 
in particular by focussing on promoting healthy ageing and preventing ill health. Older people, people 
living with frailty, and people with multiple morbidities are at greater risk of falls and fall-related 
injuries6-9. Falls and associated injuries can lead to loss of independence following hospital 
discharge10-11, and flooring interventions offer one potential solution to making healthcare 
environments age-friendly (and safer for those most vulnerable to harm in general), to improve health 
and wellbeing by preventing ill health1. Whilst evidence in this field has been growing1, there has 
been no comprehensive systematic review focussing on flooring interventions in healthcare settings 
for fall-related injury prevention. 
 
Inpatient falls are the most commonly reported safety incident in NHS hospitals12 and are of 
international concern13. Around 250,000 hospital falls occur annually in England, with about 30% 
resulting in injury, causing a significant burden for individuals, carers, and healthcare resources due 
to the costs of continued and additional care and litigation12. The estimated costs of inpatient falls to 
NHS hospitals is £630 million per year12. These costs do not account for the wider impacts to the 
health and social care system, related to rehabilitation, increased need for nursing/care homes, risk 
of recurrent falls, fear of falling, limiting activities, mobility, dependence, and the quality and longevity 
of life14. Hip fracture affects over 2500 people a year from NHS hospital falls15, and the proportion of 
hip fractures that occur in hospitals has been rising15; resulting in a 2.4 – 3.5 fold increased risk of 
mortality the following year16. Hip fractures are strongly associated with nursing home admission, 
additional formal and informal care, and further morbidity17. Whilst inpatient falls account for 
approximately 25%12 of the £2.3 billion cost of falls to the NHS estimated by NICE18, falls in other 
care settings (e.g. nursing homes and care homes) also contribute considerably to this cost19. 
Falls have a complex aetiology of intrinsic and extrinsic risk factors, affecting individuals with multiple 
morbidities, and no single solution effectively prevents them. The 2017 national falls audit estimates 
that approximately 30% of inpatient falls could be prevented, and the greatest cost savings would 
be realised if efforts were focussed on preventing severe falls12. A Cochrane review on interventions 
for hospital falls and injury prevention20 highlighted possible benefits of multifactorial interventions, 
vinyl (for falls prevention21), education, and physiotherapy. Since this review, the largest trial to date 
of inpatient falls (N=31411), a definitive cluster RCT of a multifactorial falls prevention intervention22, 
consisting of a patient risk assessment tool followed by delivery of one or more of six interventions 
(e.g. low-low beds), was found clinically ineffective. A Cochrane review on hip protectors for hip 
fractures23 revealed that compliance with this intervention was poor due to discomfort and practicality 
and was a barrier to their use. Unlike hip protectors, manipulating the environment to prevent injuries 
is a promising intervention for reducing injurious falls as it requires no compliance from patients or 
staff, and can accommodate the fact that injuries occur not just to the hip. The 2013 NICE Guideline 
161 on falls18, and the 2017 National Hip Fracture Database annual report15 have highlighted the 
pressing need to investigate environmental adaptations in older inpatients. 
A recent scoping review of flooring interventions (by co-applicant CL)1 involved a thorough search 
to identify the breadth of the evidence reported up until May 2016. Importantly, this scoping review 
did not involve a critical appraisal or systematic synthesis of the evidence, which has implications for 
the interpretation of the findings, as risk of bias can greatly determine the perceived effectiveness of 
interventions24. Additionally, the findings of at least three new/ongoing studies that we are aware of, 
are not included in the results of this scoping review; a hospital-based trial in New Zealand and a 
care home study in Sweden have since been published25, 26, and a cluster randomised trial (which 
included cost-effectiveness data) in a care home in Canada (led by our Advisory Board member 
DM)27, is currently at the stage of data cleaning pre-analysis. From the scoping review and our 
networks, we are aware of five28-32 published qualitative studies (three of which have been published 
since the scoping review30-32), and two further qualitative studies in preparation for publication (by 
AD and Advisory Board member AL). The scoping review identified 20 records of clinical 
effectiveness33-52 (nine review articles33-37,43,48-50, and 11 primary research studies of 
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randomised38,39,45 and non-randomised40-42,44,46,47,51,52 designs) and 12 records of cost-
effectiveness35,36,42,45,53-60 (which require assessment for eligibility). It is critical that these studies are 
interpreted appropriately to inform practice, since they are in some cases small38-39, or involve 
observational and quasi-experimental designs40-42,44,47,51,52, which are subject to inherent biases (e.g. 
non-comparable control groups or confounding from the different areas where flooring is laid). A 
systematic review of these studies, to include the new data from more recent studies25-27,30-32,45 will 
provide a more reliable basis for decision making on the use of shock-absorbing flooring in practice. 
There remains an unresolved debate in lab-based research as to whether the gait of older individuals 
(particularly with complex health needs) may be adversely affected by softer floors46,54,61-70, 
potentially leading to increased risk of falls. Conversely, evidence suggests that older individuals 
would benefit most from falling on softer floors54,72-76. The potential benefits and risks of shock-
absorbing floors may vary depending on the type of patient utilising them. Further adverse effects of 
shock-absorbing floors may be witnessed in staff39, who may experience greater effort is required to 
manoeuvre equipment1, manifesting in increased staff injuries. These issues have yet to be 
considered in a systematic review of clinical effectiveness studies.  
 
With the rising volume of primary research in this area, we are beginning to see evidence of shock-
absorbing floors infiltrating the NHS; but their use in practice remains inconsistent. We are aware of 
sites which have implemented shock-absorbing flooring as an innovative measure to try and 
decrease fall-related injuries. Queen Alexandra Hospital in Portsmouth, opted to install a 6.5mm 
thick flooring, following our (non-definitive) pilot study39 on an 8.3mm thick floor. A pragmatic decision 
was made (without knowing the clinical or cost-effectiveness) to use a mid-thickness floor in an 
attempt to trade-off the potential for adverse effects in staff, and in the hope that the additional 
thickness (in comparison to regular 2mm vinyl) will offer some degree of protection for falling patients. 
Other hospitals we are aware of include Bradford Hospital, and St Mary’s Hospital (Isle of Wight; 
8.3mm thick floor), who have invested in shock-absorbing flooring for their elderly care wards. York 
Hospital removed some shock-absorbing flooring due to concerns raised by staff about staff safety.  
 
Shock-absorbing floors are more expensive than regular resilient sheet floor-coverings used in 
hospitals, and other hospitals (specifically Leeds, and Southend) we know, are waiting for clearer 
guidance as to whether a shock-absorbing floor is a good investment decision, and what type of 
shock-absorbing floor to select if so. When scoping out the potential viability of a definitive hospital-
based cluster randomised trial in this area (in 2015), 28 NHS Trusts (over 40 wards) from our 
networks expressed an interest in taking part in a study should we be able to secure the funding. 
There is a clear appetite to explore the use of flooring for fall-related injury prevention, but current 
concerns exist as to whether to invest in it due to uncertainties in the evidence. The growing body of 
current evidence needs to be systematically assessed, with an exploration of heterogeneity of 
findings in different healthcare settings, and with different types of floors, to help resolve the current 
uncertainties, better inform NHS investment decisions, and to clearly identify the next steps for 
research activity (including informing the design of future studies). 
 
Evidence explaining why this research is needed now  
Fall related injuries remain a persistent and major problem in the context of our ageing population. 
The oldest age groups in society are the fastest growing sections of our society, with those aged 80 
and over, expected to represent 20% of the older population by 2050, and the worldwide estimated 
688 million people over 60 years old in 2006 projected to grow to almost two billion by 205013. These 
projections are as pertinent in the UK as they are internationally. Innovative solutions are required 
to prevent avoidable morbidity and mortality from falls. This ongoing problem is of increasing concern 
due to our ageing population and age-associated increased risks of falls and injuries77-79. Many 
hospital floors are composed of a 2mm thin vinyl on concrete, which are unable to prevent injuries 
and may exacerbate them42,47,71. Shock absorbing flooring is one potential solution1, which could be 
applicable to all patients and be non-reliant on staff/patient compliance. This is a fast progressing 
field; the Canadian Agency for Drugs and Technologies in Health published a short report in 201035 
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whereby they identified no studies of clinical and cost-effectiveness of specialised shock-absorbing 
flooring use in healthcare settings, subsequently, albeit with differences in the search and inclusion 
criteria, the scoping review published in 2017 identified 20 clinical and 12 cost-effectiveness 
records1, and since which at least two further clinical studies have been published25,26, three further 
qualitative studies have been published30-32, and another clinical and cost-effectiveness study is 
undergoing analysis27. Practitioners in healthcare settings are keen to utilise innovative measures, 
such as flooring, to reduce fall-related injuries, but making sense of the evidence is prohibited due 
to a lack of a systematic review. 
 
This research is important to quantify the potential benefits and harms in order to inform key 
stakeholders: health and social care and estates practitioners, guideline developers and others (e.g. 
litigation authorities, agencies focussed on care quality or environment, and the wider public).  
 
4. Aims and objectives  
We aim to systematically review the evidence on shock-absorbing flooring use in health and social 
care settings for fall-related injury prevention in older adults. Specifically, we will: 
1. Assess the benefits (fall-related injury prevention) and risks (falls; staff injuries) of different 
flooring systems in care settings. 
2. Assess the extent to which these benefits and harms may be modified by different study/setting, 
intervention, and participant characteristics. 
3. Critically appraise and summarise current evidence on the resource use, costs and cost-
effectiveness of shock-absorbing flooring in healthcare settings for older adults, compared with 
standard flooring. 
4. Summarise findings on the implementation of flooring interventions in the included studies. 
5. Summarise the views and experiences of shock-absorbing flooring use, of patients/residents, 
staff, and visitors in care settings. 
6. Identify gaps in existing evidence / understanding 
 
5. Research Plan / Methods  
This systematic review will include studies aimed to address the effectiveness and/or cost-
effectiveness and/or qualitative experiences of shock-absorbing flooring systems for fall-related 
injury prevention in care settings. We will follow the general approach set out in the Cochrane 
Handbook of Systematic Reviews80, incorporating the updated Risk of Bias assessment tools (ROB 
2.0 and ROBINS-I for randomised and non-randomised designs respectively2,3), and the ‘Grading of 
Recommendations, Assessment, Development and Evaluations’ (GRADE) approach with Summary 
of Findings Tables to summarise the quality of the evidence5. This review will be of relevance to care 
settings which predominantly care for older people (hospitals, long term care/nursing settings), 
where patients (or residents) are at greater risk of falls and fall-related injury19. 
 
Our interdisciplinary team comprises expertise which are subject-specific, methodological, and 
underpinned with personal experience. We are knowledgeable in: systematic review methodology; 
data synthesis; risk of bias analysis; ageing; health sciences research; health economics; estates 
and facilities management; characterising shock-absorbing materials; public engagement; patient 
perspectives; innovation in healthcare; clinical, ergonomic and human factors in falls and manual 
handling injury prevention. 
 
Health technologies being assessed  
‘Shock-absorbing flooring systems’ include floor coverings, underlays, and sub-floors considered to 
reduce the impact forces of falls. Alternative terminology may include variations on the terms: 
compliant flooring, safety flooring, soft flooring, impact absorbing flooring, energy absorbing flooring, 
low-impact flooring, dual stiffness flooring, low stiffness flooring, absorptive surfaces, cushioned 
flooring, rubber flooring, acoustic flooring, and carpet. Interventions may be flooring systems which 
have been purposely designed to prevent fall-related injuries (e.g. SmartCells, Sorbashock, Kradal), 
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thick vinyl (>5mm thick; e.g. repurposed sports floors, such as Tarkett Omnisports Excel), carpet 
with or without underlay, and other combination flooring systems (e.g. vinyl overlays with padded 
underlays, such as foam or rubber, or wooden subfloors). Fall mats will not be considered eligible 
as they are not permanently affixed to the floor and do not provide universal coverage or protection. 
We will exclude studies reporting exclusively on fall mats. We will include studies that compare 
different types of shock-absorbing flooring systems, or which compare one or more shock-absorbing 
flooring system to a standard ‘rigid’ floor (e.g. concrete, ≤2mm vinyl/resilient sheeting).  
 
Search strategy  
To reduce duplication of effort, this systematic review will build on the comprehensive search already 
conducted by co-applicant/collaborators in a scoping review1, which had a search cut-off of 20th May 
2016. The clinical (n=20), cost-effectiveness (n=12), and qualitative (n=2) records identified by the 
scoping review will be assessed for eligibility in this systematic review. The scoping review, which 
incorporated the expertise of an information scientist, involved a search of seven databases plus 
grey literature sources (Table 1). The search strategy of the scoping review (which also included 
studies exploring biomechanical efficacy and workplace safety) will be refined in scope to focus on 
identifying studies of clinical and cost-effectiveness, and qualitative experiences. The following 
electronic databases will be searched (May 2016 to present): CINAHL and MEDLINE (accessed via 
EBSCO, University of Portsmouth; see Appendix A for Medline strategy); AgeLine (accessed via 
EBSCO, Simon Fraser University, Canada); Web of Science, Scopus, and NHS Economic 
Evaluation Database (accessed via University of Portsmouth). Forward citation searching will be 
conducted on all eligible studies using Web of Science. Reference lists of any new studies identified 
post-May 2016 will be screened. A hand search of the tables of contents of Age and Ageing (the 
most predominant journal in this field to date) will be conducted from May 2016 to present. Our grey 
literature search will include a review of clinical trial registries, theses/dissertations, conference 
proceedings, and relevant websites (see Table 1), including an additional search of relevant health 
economics models from NICE (for cost of falls and staff injuries) and NHS Improvement (who support 
falls improvement and workforce initiatives within the NHS). No language restrictions will be placed 
on the search. We will use the extensive language expertise within the University of Portsmouth for 
foreign-language records which pass an initial check using Google Translate.  A review author will 
work through the eligibility checklist (and if relevant, the data collection form) alongside someone 
who speaks the appropriate language. Relevant sections of the article will be translated in order to 
complete the data collection form; these will be checked by a second person. 
 
Table 1. Sources of academic and grey literature: differences between the scoping review 
and the present systematic review. 
Search type 
 
Sources of literature included in the scoping review Sources to be 
included in this 
systematic review 
Academic 
search 
AgeLine (EBSCO; 1978 to May 2016) Yes (May 2016 -) 
CINAHL Complete (EBSCO; 1937 to May 2016) Yes (May 2016 -) 
EBM Reviews (OVID; 1991 to May 2016) Out of scope 
Ergo-Abs (EBSCO; 1985 to May 2016) Out of scope 
MEDLINE (Ovid; 1950 to May 2016) Yes (May 2016 -) 
SPORTDiscus (EBSCO; 1830 to May 2016) Out of scope 
Web of Science (Thomson Reuters; 1898 to May 2016) Yes (May 2016- )  
- Scopus (May 2016- ) 
- NHS EED  
Grey 
literature 
search (1990 
to present) 
Clinical trial registries:  
● Clinicaltrials.gov   WHO International 
Clinical Trials 
Registry Platform ● Controlled-trials.com 
Theses/dissertations:  
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● ProQuest Theses and Dissertations Yes 
Abstracts/conference proceedings for target associations:  
● Bioengineering Out of scope 
● Annual Conference of the IEEE Engineering in 
Medicine and Biology Society 
Out of scope 
● ASME Summer Bioengineering Conference Out of scope 
Biomechanics  
● Annual Conference of the American Society of 
Biomechanics 
Out of scope 
● Biennial Meeting of the Canadian Society of 
Biomechanics 
Out of scope 
● Congress of the International Society of 
Biomechanics 
Out of scope 
Falls prevention  
● Biennial Conference of the Australian and New 
Zealand Falls Prevention Society 
Yes 
● International Conference on Fall Prevention and 
Protection 
No (has not been re-
run) 
● International Society for Posture and Gait Research 
World Congress 
Yes 
Gerontology  
● Canadian Association on Gerontology Annual 
Scientific and Educational Meeting 
Yes 
● Gerontological Society of America's Annual Scientific 
Meeting 
Yes 
● World Conference of Gerontechnology Yes 
● World Congress of the International Association of 
Gerontology and Geriatrics 
Yes 
Websites of target organisations:  
● Agency for Healthcare Research and Quality (AHRQ) Yes 
● American Society for Testing and Materials (ASTM) 
International 
Out of scope 
● Canadian Agency for Drugs and Technologies in 
Health (CADTH) 
Yes 
● Occupational Safety and Health Administration 
(OSHA) 
Out of scope 
● OpenSIGLE OpenGrey 
● Parachute Canada Yes 
● The National Institute for Occupational Safety and 
Health (NIOSH) 
Yes 
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● UK Health Technology Assessment Yes plus other NIHR 
funded programmes 
● US Center for Health Design Yes 
● WHO Health Evidence Database (HEN)  Yes 
 - NICE guidelines  
 - NHS Improvement 
Hand 
searching 
(1990 to 
present) 
Reference lists of all eligible records Yes 
Tables of contents of the journal ‘Age and Ageing’ Yes 
Consultation 
with experts 
(NA) 
We will consult with content experts and the Research 
Advisory Panel to identify individual records not already 
uncovered by our academic database, grey literature and 
hand searches. 
Yes 
 
Review strategy and strategy for reviewing literature  
All references will be imported into a reference management software, Endnote. We will manage the 
review strategy with the software ‘Covidence’81, which supports international collaboration through 
sorting for duplicates, the screening, data collection, and risk of bias assessment processes, to 
enable tasks to be done independently in duplicate, facilitating identification and resolution of 
differences of opinions, and producing a PRISMA flow diagram82. Data will be analysed in RevMan83, 
and Summary of Findings Tables created with GRADE Pro84 (and guidance from the GRADE 
handbook).85 
 
Titles, abstracts, and full reports will be screened in duplicate using an eligibility checklist (based on 
the inclusion/exclusion criteria listed below). All records included in the clinical and cost-effectiveness 
sections of the scoping review will be assessed at the full report stage. From the results of the 
updated search, we will begin by screening titles, and those that look potentially relevant will be 
reviewed in abstract form. Full reports will be obtained for abstracts which appear definitely or 
possibly relevant. Disagreements will be resolved through discussion including a third independent 
arbitrator. The selection process will be documented in a PRISMA flow diagram82.    
 
Risk of bias assessment will be undertaken using the updated Cochrane risk of bias tool (ROB 2.0)2 
for randomised trials (including individually and cluster randomised, and cross-over studies). The 
ROBINS-I (Risk Of Bias In Non-randomised Studies of Interventions) tool3, will be used to assess 
observational studies and non-randomised experimental designs. Review authors will not be blinded 
during risk of bias assessments, however where they have been involved in co-authoring an included 
study (CL, AD), assessments will be undertaken by at least two other independent reviewers (OO, 
BK, LF). Our public involvement members will be involved in checking the integrity and transparency 
of the risk of bias assessments. We will seek further information from study authors where required 
if there is inadequate information to form a risk of bias judgement; we will approach study authors 
with open-ended questions, asking to describe the relevant study processes in more detail, so to 
avoid overly positive answers. 
 
Design and theoretical/conceptual framework  
This systematic review will incorporate experimental, quasi-experimental, observational, and 
qualitative studies. Whilst randomised trials of flooring interventions are feasible (given appropriate 
resources), the nature and logistics of the intervention make observational and opportunistic quasi-
experimental designs far more practical; therefore we will include non-randomised studies with the 
view to systematically report their findings and limitations, to better inform practice. To overcome 
variations in terminology usage, regardless of how study authors label their study designs, we will 
utilise the tables of study design features presented in the Cochrane Handbook80 to classify included 
studies by their component design features. The following examples will be eligible: 
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- Randomised controlled trials, these may be randomised at the individual, or (more likely) cluster 
level (e.g. with the unit of allocation by room/area/facility), non-random methods of allocation 
(quasi-experimental studies, as per further examples below) will also be included; 
- Interrupted times series (e.g. evaluating a change in trend in outcome measures before and after 
shock-absorbing flooring installation); 
- Controlled before and after studies (e.g. non-randomised allocation to shock-absorbing flooring 
or control, where outcomes are measured concurrently in groups of participants residing in areas 
with different floors, before and after a change in floor in at least one group); 
- Cohort studies (e.g. prospectively or retrospectively observing groups of patients residing in 
areas with or without shock-absorbing flooring); 
- Case-control studies (e.g. retrospectively evaluating where patients with various classifications 
of fall-related injuries fell, to see the effect of flooring type on outcome). 
- Partial and full economic evaluations, based on a single study or model. 
- Qualitative studies involving interviews, focus groups, questionnaires or surveys, to explore 
experiences, attitudes, and perceptions towards flooring interventions. 
 
Simple before and after studies measuring quantitative outcomes, with no evaluation of time trends 
(i.e. a series of at least three observations prior and three observations post intervention), or 
concurrent control, will be excluded.  
 
The following proposed theoretical framework (Figure 1) conceptualises the causal pathway 
between shock-absorbing floor systems and their outcomes (falls, fall-related injuries, adverse 
events – staff injuries), and potential (often related) moderators of that relationship (effect modifiers). 
The purpose of this framework is to help direct the review process, by informing data collection, risk 
of bias assessment (particularly in relation to confounding), exploration of heterogeneity, and 
analysis of the data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Theoretical framework of potential effect modifiers. 
 
Target population  
The target population for this review is broadly, older people in healthcare settings. Notably, the 
adverse effects may be witnessed in staff who are occupying the same environment, due to the 
potential for increased effort to undertake tasks (e.g. moving wheeled equipment, such as beds, 
trolleys, and hoists). Staff and visitors, along with patients/residents may also offer useful qualitative 
insights into flooring use. 
 
Flooring 
system Outcomes 
 
Participant characteristics 
Risk factors for falls / injury, e.g.: 
Age 
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Body Mass Index 
Bone density/osteoporosis 
Medications 
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Walking aid type/use 
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Study / setting 
characteristics 
Setting (acute, sub-acute, 
long-term care) 
Risk of bias 
Study design 
Staffing levels 
Wheeled equipment in use 
Concurrent fall & injury 
prevention practices 
Staff duties on floor 
Floor cleaning regimes 
Interventions 
 
Impact force reduction 
Push-pull forces 
Materials (e.g. rubber, 
foam, vinyl, carpet, etc.) 
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Age of floor (wear) 
Manufacturer/product 
Sub-floor 
Floor coverage (areas of 
use) Po
te
nt
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Inclusion/Exclusion Criteria  
Population: Studies must focus on adult populations in healthcare settings to be included in this 
review. Studies focussed solely on paediatric care settings will be excluded. We will be pragmatic, 
and open to different definitions of ‘older adults’ and will not have a set cut-off criterion for age, since 
it is acknowledged that chronological age may not be a good indicator of frailty86,87. Due to the nature 
and purpose of the intervention, we anticipate that studies will largely be conducted in high risk 
environments where older people are the predominant population and falls are more likely.   
 
Interventions: Studies must compare different types of flooring, with at least one intervention 
classifiable as a ‘shock-absorbing’ floor, as per our definition above. Studies which include flooring 
as one component of a package of multiple interventions, in which the effects of the floor cannot be 
disentangled from other concurrent interventions, will be excluded. 
 
Outcomes: Whilst we would expect quantitative studies to report on outcomes related to falls and 
fall-related injuries as a minimum, the reporting of specific outcomes does not form part of the 
inclusion criteria for our review. Rather, we will consider the reporting of outcomes as part of our risk 
of bias assessments and assessment of reporting/publication bias. 
 
Setting: Studies must have been conducted in a care setting (defined below) to be included in this 
review. This includes hospitals (acute, sub-acute), intermediate and long-term care settings (nursing 
and care homes). Studies conducted in people’s own homes, or other settings (e.g. playgrounds, 
sporting venues) will be excluded. 
 
Study design: We will include primary quantitative or qualitative research studies; quantitative 
studies must have a concurrent control group, or an analysis of trends over time (interrupted times 
series) to account for seasonal effects. We will not apply a threshold for risk of bias to be included, 
rather, we will address the potential influence of risk of bias in the analysis and interpretation of our 
findings, e.g. through subgroup and sensitivity analyses where appropriate. Simple before-and-after 
studies will be excluded.  
 
Setting/context  
Care settings will be broadly defined as88: 
● Care home environments (a facility that meets the following criteria: provides communal living 
facilities for long-term care; provides overnight accommodation; provides nursing or personal 
care; and provides for people with illness, disability or dependence). 
● Hospital environments (a facility that meets the following criteria: provides communal care where 
there is an expectation that this care is time limited; provides overnight accommodation; provides 
nursing and personal care; and provides for people with illness and disability). 
Data collection  
Our data collection will be underpinned by our theoretical framework of potential effect modifiers 
(Fig.1). We will develop and utilise a data collection form (to be piloted on three included studies, 
and amended as required), which will be uploaded in to the software ‘Covidence’.  
Data collection will include the following key components of information, details within which will be 
informed by our theoretical framework: 
● Study identification (and linked publications) 
● Time/duration and geographical place of conduct 
● Participant characteristics  
● Intervention(s) 
● Control(s) 
● Outcome data acquisition: Falls reporting (e.g. retrospective database review; prospective 
daily checks of patient notes; staff recall; triangulation of sources); Classification system of 
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injuries; Identification of fractures (confirmation of diagnosis/type of fractures included); 
Identification of adverse effects. 
● Setting 
● Study design characteristics 
● Risk of bias assessments 
● Outcomes and analyses (we will extract summary effect estimates where possible, or collect 
raw data to enable our own calculations if feasible). 
● Patient and public involvement in the research 
● Follow-up questions for study authors (Missing and unclear information will be flagged). 
 
Assessment of risk of bias  
Risk of bias assessments will be conducted using the ROB 2.02 and ROBINS-I3 tools for randomised 
and non-randomised studies respectively, at the level of the study results. We will focus on assessing 
rate and risk of injurious falls, rate and risk of falls, as well as adverse events in staff. For randomised 
trials, we will assess study results for risk of bias across the following five domains: (1) Bias arising 
from the randomization process; (2) Bias due to deviations from intended interventions; (3) Bias due 
to missing outcome data; (4) Bias in measurement of the outcome; (5) Bias in selection of the 
reported result. Cluster trials will also include an assessment of (1b) bias arising from the timing of 
identification and recruitment of individual participants. The results of non-randomised studies will 
be assessed across seven domains. The first three of these domains will replace ‘bias arising from 
the randomisation process’: (1) Bias due to confounding; (2) Bias in selection of participants into the 
study; (3) Bias in classification of interventions; the final four domains align with the final four domains 
of the ROB 2.0 tool. Supporting information and justification for judgements (high; low; some 
concerns) will be recorded for each domain. We will follow the guidance to derive overall summary 
risk of bias judgements for each outcome (high; low; some concerns), which will be used to inform 
our statistical analyses and GRADE assessments. 
 
Data analysis (quantitative studies)  
Assessment of reporting biases: Where possible, we will draw funnel plots with different plotting 
symbols to identify subgroups (as specified below). We will only test for funnel plot asymmetry if 
there are sufficient data (at least 10 studies to be combined), and will use visual inspection of the 
plots to make sense of the findings. Our aim is to reduce the risk of publication bias affecting our 
results by conducting a thorough search and communicating with researchers in the field.  
 
Dealing with missing data: We will contact study authors for data missing from the reports. If 
missing data are from participant/cluster dropouts, we will conduct analyses based on the available 
data and include an assessment of the problem as part of our risk of bias judgements.  
 
Measures of treatment effect: Rate of falls, rate of injurious falls, and rate of fracture will be 
reported using incidence rate ratios and 95% confidence intervals. The number of fallers, number of 
participants with fall-related injuries, and number of participants with fall-related fracture, will be 
described using risk ratios and 95% confidence intervals. Where available we will also report hazard 
ratios for falls (to include all falls from recurrent fallers), since this will provide a more powerful 
analysis of an increase in falls in the intervention group (should one exist). Where adjusted and 
unadjusted rates are presented in randomised trials, we will use the unadjusted figures, unless the 
adjustment is for clustering. For non-randomised studies, we will record the unadjusted and adjusted 
estimates and note the factors adjusted for. Where multiple adjusted estimates are presented, we 
will extract the estimate highlighted as the primary model by the authors, or where this is unclear, 
take the model which has adjusted for the most covariates. Where summary effect estimates (rate 
ratios or risk ratios) are not reported, we will calculate them where feasible using the raw data (i.e. 
number of falls, total length of person-time monitored, total number of participants observed in each 
group), or by converting any reported odds ratios using an Excel spreadsheet which has built-in the 
formulas provided in the Cochrane Handbook80.  
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Where studies present a break-down of the severity of injuries (as ordinal outcome data, e.g. none, 
mild, moderate, severe, death), we will present these descriptively, and if studies have used similar 
categorisation systems, using figures where feasible (e.g. stacked bar graphs), since proportional 
odds ratios are difficult to interpret (less useful for end users of the review), and the alternative of 
using a cut-off point to dichotomise the data seems redundant and difficult to justify since we are 
already investigating injurious falls and fractures as separate outcomes. Adverse events to staff will 
be reported as a risk or rate ratio (per 100 working staff-days) where possible, or as the number of 
events observed during the follow-up period, if no clear denominator is known. 
Unit of analysis issues: To avoid unit of analysis issues (including the same group of participants 
more than once in an analysis), we will be mindful of trials with multiple associated publications, or 
with multiple intervention groups; in the case of multiple study arms, we will either combine the 
groups (if logical) or include only one pair-wise comparison (intervention versus control) in any one 
analysis. Cluster randomised trials will be clearly identified in the review and the way that the data 
have been dealt will be described. Where clustering has not been taken into account, we plan to 
adjust the estimates using an intra-cluster correlation coefficient borrowed from another similar 
study80. 
 
Assessment and investigation of heterogeneity: Where evidence exists from randomised and 
non-randomised studies, we will report the data separately, giving more emphasis to the findings 
from randomised trials. Non-randomised studies will be organised according to whether data 
collection was prospective or retrospective, and if controls were concurrent or historical. Where 
feasible, we will plot data onto forest plots, using the generic inverse variance data type in RevMan, 
and explore heterogeneity. 
We will explore heterogeneity irrespective of whether we decide to pool studies in a meta-analysis. 
Heterogeneity will be assessed through a combination of visual inspection of the forest plots, along 
with consideration of tests for homogeneity (Chi² with statistical significance set at P < 0.10), and 
measures for inconsistency (I²) and heterogeneity (tau2). 
 
The following study and intervention characteristics will be explored via subgroups, where feasible: 
- Study design (randomised, type of non-randomised study) 
- Study setting (hospital, care home) 
- Acuity of care (acute, sub-acute, intermediate, long-term care) 
- Flooring type (novel shock-absorbing flooring, thick vinyl/vinyl & underlay, carpet, wooden 
subfloor)  
We will not explore patient level characteristics via subgroups as this level of data is more suited to 
individual-patient data meta-analysis, which is beyond the scope of this review. However, we 
anticipate that study level characteristics related to setting and the acuity level of care provided, will 
overlap with differences in patient-level factors, which we will assess and comment upon qualitatively 
by reviewing the Tables of Included Studies. 
 
Sensitivity analyses: Sensitivity analyses will be undertaken to determine the influence of:  
- risk of bias (removing studies at high risk of bias); 
- choice of effect estimates (e.g. where multiple adjusted estimates are presented in observational 
studies, the analysis will be run on the most optimistic and pessimistic scenarios). 
- Adjustment for clustering where an intra-cluster correlation coefficient has been borrowed from 
another similar study; we will assess the impact of opting for more or less conservative 
adjustments.  
 
Data synthesis: Should meta-analysis be viable, we will opt to combine studies using a random-
effects model, assuming that intervention effects are likely to vary across studies (based on our 
theoretical framework of potential effect modifiers; Figure 1). If appropriate, we will combine the data 
from RCTs and non-RCTs to provide an overall summary effect estimate. 
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Measurement of costs and outcomes  
There is no core outcome set for shock-absorbing flooring interventions specifically, however a 
common outcome data set for fall injury prevention trials has been developed89, albeit with a focus 
on community-dwelling populations. This consensus statement provides a definition for a fall as “an 
unexpected event in which the participants come to rest on the ground, floor, or lower level”. It 
recommends falls be summarised by trialists as number of falls, number of fallers / non-fallers / 
frequent fallers, fall rate per person year, and time to first fall. For injuries, the recommended 
measure is the number of radiologically confirmed peripheral fracture events per person year (to 
include the limbs and limb girdles). It is recommended that investigators summarise injury data as 
peripheral fracture rate per person-year of follow-up, number of peripheral fractures, number of 
people sustaining peripheral fractures, and number of people sustaining multiple events. It is 
recommended that primary analyses of fall and injury data should not be adjusted for physical 
activity, and reporting should include the absolute risk difference. It is recommended89 that the 
psychological consequences of falling (defined as “the degree of confidence a person has in 
performing common activities of daily living without falling”) are measured using the modified Falls 
Efficacy Scale, and health related quality of life is measured with the Short Form 12 (SF12) version 
2 and European Quality of Life Instrument (EuroQoL EQ-5D).  
 
An international consensus statement for trials on hip protectors90 proposes the outcomes of: hip 
fractures (defined as proximal femoral fractures to include subtrochanteric fractures, and 
periprosthetic fractures, but not femoral shaft fractures), adherence, falls (total and injurious), quality 
of life, adverse effects, other fractures, cost–effectiveness and cost–utility analyses. 
 
There are some key differences to consider in relation with the present review and these core 
outcome sets, namely: (1) it is more common for rates of falls and injuries to be presented in terms 
of 1000 patient bed-days in institutional settings (versus person-years in the community); (2) a 
number of the items on the Falls Efficacy Scale have limited applicability to individuals in institutional 
settings, so it is unlikely to be used in this context; (3) hip protectors target a more specific area of 
the body than shock-absorbing flooring, so trials on flooring are likely going to want to capture 
broader effects. Taking into consideration these related core outcome sets, and their differences in 
foci with the current review, and through discussion with our public involvement group, and wider 
stakeholder engagement we have undertaken in the field91, we plan to focus on the following 
outcome measures: 
 
Primary outcomes: 
(1) Injurious falls rate per 1000 patient-bed days; (2) Falls rate per 1000 patient-bed days. 
 
Secondary outcomes:  
(1) Fractures per 1000 patient bed days; (2) Hip fractures per 1000 patient bed days; (3) No. of 
fallers; (4) No. of fallers with injuries (none, minor, moderate, severe, death); (5) No. of adverse 
events (staff injuries); (6) No. of fractures;(7) No. of hip fractures; (8) Qualitative outcomes (e.g. staff, 
patients/residents, and visitors attitudes, views, and experiences).(9) Economic outcomes (to include 
assessments of quality-adjusted life years); (10) Process outcomes (e.g. ease of, or problems with, 
flooring installation). 
Economic evaluation 
We shall align our approach for the incorporation of costs data to an exemplar systematic review by 
Garrison and colleagues92. One reviewer (LF) will extract all data from included economic 
evaluations, which will be checked by an expert reviewer (JR). The data extraction form for economic 
evaluations will be based on the format and guidelines used to produce structured abstracts of full 
economic evaluations for inclusion in the NHS Economic Evaluation Database, adapted to reflect 
specific design features of this review. Data extraction will include general study characteristics (e.g. 
country, settings, aims) and methodological aspects related to economic evaluations. We will collect 
the following economic variables, if reported: costs of flooring (purchasing, installation, 
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maintenance); costs of falls based on injury, such as hospital resources (e.g., increased length of 
stay, additional surgery needs), post-discharge healthcare costs (e.g. hospital readmission, 
outpatient visits); utility measures, such as quality of life, life years and quality adjusted life years; 
and summary measures, including incremental cost-effectiveness ratios (ICERs), net monetary 
benefits, and value of information (VoI).  
 
Data extraction will include items on economic study type, analytic perspective, study population, 
modelling and statistical extrapolation, setting, dates to which data relate/time horizon of costs and 
effects, clinical and epidemiological data, data sources, methods used to obtain data, link between 
effectiveness and cost data, details and methods of associated effectiveness studies, source(s) of 
unit cost data, currency, resource use and costs, methods used to allow for uncertainty, synthesis of 
costs and benefits, incremental cost-effectiveness results, authors conclusions, comments. 
 
Economic evaluations will be classified by type (Partial evaluations: ‘outcome description’, ‘cost 
description’, ‘cost-outcome description’, ‘efficacy or effectiveness evaluation’, or ‘cost-analysis’; Full 
economic evaluations: ‘cost-effectiveness analysis’, ‘cost-utility analysis’, or ‘cost-benefit analysis’) 
and as either an economic evaluation based on a single study or a model-based economic 
evaluation. Where necessary, we will seek additional information from study authors. 
 
We will assess the methodological quality of included economic evaluations through the use of the 
risk of bias tool and recognised checklists92 based on guidelines for authors and peer reviewers of 
economic submissions to the British Medical Journal (for economic evaluations based on a single 
study), and for quality assessment in economic decision-analytic models (for model-based 
economic evaluations). Checklists will be completed independently by two reviewers (JR and LF) 
and disagreements will be resolved through discussion. 
 
We will tabulate and summarise the results of included economic evaluations narratively in the text. 
We will adjust all costs to 2019 Pound Sterling values using Gross Domestic Product deflators, and 
use relevant exchange rates for international comparisons. 
 
Qualitative evaluation 
We will incorporate qualitative evidence into the review using a meta-aggregative approach to 
qualitative synthesis (following the guidance of the Joanna Briggs Institute95). An appealing feature 
underpinning this approach, is that it seeks to derive generalizable statements, in the form of 
recommendations that can be used to guide end-users (practitioners and policy makers). Studies 
will be assessed using the Joanna Briggs Institute’s critical appraisal tool for qualitative research95 
and data will be extracted by two independent reviewers (LF and AD) and using a third reviewer for 
arbitration if required (and to ensure duplicate independent quality assessment of AD’s paper).  
 
Data to be considered ‘findings’ for the purposes of the review, will be the themes/metaphors 
presented in the results sections (and discussion sections, if relevant), defined as “a verbatim extract 
of the authors analytic interpretation accompanied by either a participant voice, or fieldwork 
observations or other data”. Synthesis will follow a three-step process (1. Extraction of all findings 
from included papers, with an accompanying illustration and rated level of credibility; 2. Developing 
categories for findings which are sufficiently similar; 3. Developing one or more synthesized findings 
of at least two categories). Qualitative study selection will be supported via Covidence, as with our 
other study types. Data analyses will be conducted using QSR NVivo software (which we have 
utilised for qualitative synthesis previously96). 
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Confidence in Cumulative Evidence 
Quantitative Evidence: We will assess the quality of evidence across the included studies at 
outcome level for each comparison using GRADE84, and incorporate these assessments into ‘Grade 
profile’ and Summary of Findings (SoF) Tables using the GRADEpro software85. Our main 
comparison will be ‘shock-absorbing flooring (all types) versus standard flooring’, and we will include 
separate SoF tables for hospitals and care homes. Supplementary SoF tables will be developed for 
different types of shock-absorbing flooring (e.g. specially designed ‘health’ floors; sports floors in 
care settings; carpet / wooden subfloors) versus standard flooring (e.g. ≤2mm resilient sheet 
vinyl/lino on concrete or wooden subfloor), and for head-to-head comparisons of different shock-
absorbing flooring interventions. 
 
We will include the following outcomes: (1) injurious falls rate per 1000 patient-bed days, (2) falls 
rate per 1000 patient-bed days, (3) fractures per 1000 patient bed days, (4) hip fractures per 1000 
patient bed days; (5) number of fallers, (6) number of fallers with injuries (none, minor, moderate, 
severe), and (7) number of adverse events (e.g. staff injuries). The GRADE system provides a grade 
of the overall quality of the evidence for each outcome on one of four levels: high, moderate, low, 
very low. 
We will use the following five GRADE criteria to assess the quality of evidence: risk of bias; 
indirectness of evidence; inconsistency of effect (heterogeneity); imprecision of the effect estimates; 
and risk of publication bias80. In the first instance, two review authors will independently assess the 
GRADE criteria for all the above outcomes in a purposefully designed form. We will justify each 
grading decision. We will then compare the independent assessments of both the authors, with the 
aim to resolve any discrepancies in the decisions by discussion and as appropriate, by consulting a 
third review author. Once a consensus is reached, one review author (LF) will transfer the agreed 
data to the GRADEpro table, using the GRADEproGDT software (GRADEproGDT), and create the 
SoF table.   
The Summary of findings (SoF) tables will include a brief description of the population, settings, 
intervention and the comparison intervention, in addition to: 
1. A measure of the typical burden of the outcomes such as illustrative risk based on data 
derived from the studies (control groups) included in the review;; 
2. Absolute and relative magnitude of effect; 
3. Numbers of participants, and studies addressing each outcome; 
4. A GRADE assessment of the overall quality of the body of evidence for each outcome;  
5. Comments such as interpretation of the quality of evidence, and clinical relevance; 
6. Explanations to support upgrading or downgrading decisions of the grade assessment.  
We will provide supplementary ‘Evidence Profile’ tables to breakdown the quality assessments in a 
clear and transparent format5.   
Qualitative Evidence: We will follow the CERQual group’s recommendations to assess the quality 
of qualitative evidence included in the review97. We will assess each review finding based on 
methodological limitations, coherence, adequacy of data, and relevance98. We will make an overall 
assessment of confidence for each review finding on one of the four levels: high, moderate, low, very 
low. We will create ‘CERQual Evidence Profile’, and ‘Summary of Qualitative Findings (SoQF)’ 
tables. 
 
We will include the following information in the Evidence Profile: i) a summary of each review finding; 
ii) an explanation of the assessment made for each component for each review finding; iii) an overall 
CERQual assessment for each individual review finding; iv) an explanation of the overall CERQual 
assessments; v) reference to the studies contributing data to the review findings. SoQF will 
summarise the key review findings, and we will include the following three elements in the table: i) 
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summary of each review finding; ii) an overall CERQual for each review finding; iii) reference to the 
studies contributing data to the review finding. 
 
6. Dissemination, Outputs and anticipated Impact  
Our approach is underpinned by the Knowledge to Action Framework99, and will ensure involvement 
of knowledge users with researchers throughout the research process. A previous stakeholder 
symposium91 has informed the identified problems to be addressed in this review (namely: 
addressing questions of clinical and cost-effectiveness, to address concerns with the perceived 
financial barriers as well as barriers to installation), and we will continue to engage with stakeholders 
to ensure our outputs can be adapted to local contexts, barriers to uptake are considered, and 
knowledge use can be monitored. 
 
What do we intend to produce from our research?  
The following outputs will be produced from this research: 
● A peer-reviewed, (gold) open access journal publication of the review findings 
● A presentation at an international conference (e.g. Biennial Global Ageing Conference) 
● A presentation at a national conference (e.g. British Geriatrics Society Autumn Meeting) 
● A webinar presentation 
● A peer-reviewed, (green) open access journal publication of the review protocol 
● A registration entry on the PROSPERO database 
● Press release/social media with an item in relevant media outlets (e.g. The Conversation; 
The HEFMA Pulse magazine) generating national/international media attention with Creative 
Commons License for re-use  
● A half-day stakeholder symposium, the outputs of which will be made available online 
● A short video distilling the review findings via patient stories 
● Knowledge-To-Action Reports tailored to NHS Chief Executives, care home managers, and 
estates/facilities managers, healthcare designers and builders. 
 
How will we inform and engage patients, NHS and the wider population about our work?  
We will consult with key stakeholders and a range of potential knowledge users at each stage of our 
review (i.e. small group meetings, one-to-one discussions, videoconferences, teleconferences, and 
email). Our Advisory Board includes the following knowledge users: Falls in older people NICE 
Guideline Developer; Safety and Improvement Clinical Lead; director/chairman of the Health Estates 
and Facilities Management Association; public members; shock-absorbing flooring researchers from 
health sciences and engineering disciplines). Collectively, members of the Panel possess the 
relevant expertise and decision-making authority to critically evaluate and implement shock-
absorbing flooring systems in high-risk environments such as hospitals and long-term care, and 
utilise systematic review evidence to inform future research. 
An interactive process of communication between researchers and the Advisory Board will be used 
throughout all stages of the review process. We will involve the Board in a number of important ways: 
(1) in providing input on the design and implementation of the review; (2) as members of the project 
team who attend project meetings and inform us of emerging primary research evidence; (3) in the 
interpretation of findings and identification of research gaps; and (4) in the packaging and 
dissemination of the review's findings in a form that is relevant, practical and easily interpreted by 
other decision-makers and knowledge users. 
We also plan to engage with targeted and wider members (falls prevention / safety clinical leads; 
nursing home managers; NHS hospital executives; members of the public; NHS estates managers) 
of our broader networks at the outset, mid-point, and conclusion of the grant period, to incorporate 
their information needs, keep them engaged, and provide a broader base for knowledge translation 
at regional, national, and international levels. We recognise the importance of professional, 
organisational, and systems level influences in the uptake of innovations, and that there are 
preferences for different types of evidence across professional groups100. Our engagement strategy 
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therefore targets individuals and organisations at these different levels of influence, and our 
dissemination plan includes the reframing of our findings into different formats (academic 
publications; conference presentations; Knowledge-to-Action Reports; video depicting patient stories 
and need; webinar; a half-day symposium; and social media and press).  
 
Our end-of-grant dissemination plan matches knowledge translation strategies to each of our target 
audiences to support the advancement of health-related knowledge. To disseminate findings to 
stakeholders from a range of sectors, and to capitalise on the power of in-person communication, 
we will host a half-day Stakeholder Symposium to which we will invite individuals representing 
healthcare, occupational health, building design and construction, government, housing, flooring 
manufacturers, and research. This approach has been successfully implemented in Canada as part 
of the project related to the scoping review91.  
To disseminate findings to a broader geographic audience of stakeholders from a range of sectors, 
we will host a webinar and produce and distribute Knowledge-to-Action Reports. To reach academic 
stakeholders, we will prepare and submit both a conference abstract and open-access peer-
reviewed journal article with the study results. It has been highlighted that service commissioners 
draw on a range of evidence, including alternative evidence such as patient stories97. With this in 
mind, we will work with our public involvement group (and other members of the public as required) 
to produce a short video, which incorporates compelling patient narratives that elaborate upon the 
bottom line evidence found in the systematic review. We will produce this video in our state-of-the 
art simulation in health care centre (ward and care home environment), and with the expertise of the 
University of Portsmouth Media Production Centre. This video will be accessible to the public and 
linked to our other dissemination outputs, including social media and press releases. Our press 
release will include submission of an article to The Conversation (https://theconversation.com/uk), 
an independent media outlet which many national newspapers and other media sources (across the 
world) re-use content from under their Creative Commons License. Publishing via The Conversation 
also enables authors to track the readership numbers and wider dissemination of the article. We will 
evaluate the success of our end-of-grant dissemination efforts through a variety of means, such as 
tracking event attendance, event evaluation forms, downloads and citations of our scientific journal 
article, and distribution numbers for the Knowledge-to-Action Reports. The review's findings and 
outputs will be made openly available via the Open Science Framework and will help decision-
makers understand the current evidence base on shock-absorbing flooring that aims to prevent fall-
related injuries. 
Our engagement plan with stakeholders throughout this review will better enable us to adapt the 
presentation of the review findings to different stakeholders and contexts. Aside from our regular 
Advisory Board meetings and Public Involvement meetings, we will seek to engage with key parties 
through the use of our extensive personal and professional networks, for example:  
● AD manages the University of Portsmouth Ageing Network >520 internal and external 
members (including NHS, local authorities, nursing and care homes, voluntary sector 
organisations) and >120 public engagement members;  
● AD sits on two expert advisory groups and a community of practice for the Healthy Ageing 
Programme run by the Wessex Academic Health Science Network (AHSN). The Wessex 
AHSN also disseminates information to 3000 members regionally and has extensive links 
with AHSNs across the country. 
● AD maintains a list of 86 stakeholders (from NHS, public, and wider organisations, including: 
NHS Property Services Ltd; Architects for Health; Office of Quality and Patient Safety, The 
Joint Commission, USA; and Canadian Patient Safety Institute) who have expressed a 
specific interest of being kept up-to-date with shock-absorbing flooring research;  
● JW regularly communicates with four regional falls networks across the country 
(approximately 250 members); 
● JW is on the Steering Group for the National Inpatient Falls Audit at the Royal College of 
Physicians, which links with Chief Executives of the 19 Trusts registered to the audit.  
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● Together, we share contact information with members of the flooring industry who have an 
interest in operating in this field (e.g. Tarkett, Polyflor, Altro, Gerflor, Kradal, SmartCells). 
Further key parties will be identified via the networks above (by asking key individuals to link us in 
with their networks) and through facilities such as the CHAIN Network (http://www.chain-
network.org.uk/) and social media (LinkedIN, Twitter). 
 
Our collaborator KFS is the External Promotion and Liaison Lead, for the School of Health Sciences 
and Social Work, and she will oversee our engagement plan, beginning at the start of the project by 
disseminating news of our work, inviting feedback, and updating our contacts database with the 
details of interested parties. A newsletter with a brief preferences survey will be disseminated mid-
way through the project, to help us shape our dissemination products, and invite people to attend 
the stakeholder symposium. As well as a means to disseminating the findings, the stakeholder 
symposium will include workshop activities to enable stakeholders to discuss the barriers to uptake 
of the research findings, how the findings will need to be tailored to their contexts, and to look for 
solutions to issues raised. 
 
How will our outputs enter our health and care system or society as a whole?  
We anticipate our outputs to be incorporated into clinical guidelines (updates to the NICE CG161), 
and other practice guidelines internationally, e.g. in the USA, the Eastern Association for the Surgery 
of Trauma has issued practice guidelines in this area, noting our research101. We will engage with 
NHS Property Services to facilitate the uptake of the outputs into decision-making for refurbishment 
schedules of their 3500 properties large estate and new-building works. Our engagement with clinical 
falls specialists, Chief Executives, estates and facilities managers, nursing home managers, and 
Academic Health Science Networks, and higher level organisations (e.g. NHS Improvement; Joint 
Commission, USA; Canadian Patient Safety Institute) will facilitate the spread of knowledge, from 
bottom-up and top-down perspectives. 
 
What further funding or support will be required if this research is successful?  
We plan to carry forward the work of this review with future primary research to address gaps and 
uncertainties highlighted by the evidence (we may approach NIHR, UKRI, industry, or charities for 
such funding). Should the review highlight clinical effectiveness for particular groups or contexts, we 
will next seek to address the barriers to implementation that will be discussed at our stakeholder 
symposium. We anticipate one potential barrier to implementation to be related to staff concerns 
over the use of wheeled equipment on the floor. This may be tackled through, for example, working 
with industry to improve the rolling resistance of shock-absorbing flooring products, exploring the 
use of wheeled equipment within the system (e.g. are there more appropriate products with larger 
wheels, assistive technologies); looking at the policies and staffing factors surrounding manual 
handling to see where improvements could be made.  
 
What are the possible barriers for further research, development, adoption and 
implementation?  
A potential barrier to uptake is the possibility for inconclusive findings of the review, or uncertainty 
around the trade-off between potential benefits and harms of the intervention. We hope this risk will 
be somewhat mitigated by the emerging evidence which will be incorporated into this review, and 
our attempt to meta-analyse results where feasible and appropriate. In addition, the incorporation of 
economic data we hope will aid decision making, should a potential for harm be demonstrated. 
Whatever findings arise from this review, it will still lead to better available information to inform 
decisions than is currently available, and the findings will therefore be valuable to practice. 
 
One concern raised at our previous stakeholder symposium91 was around feasibility of installation. 
To address this concern we will include process outcomes in the review, to detail any issues 
experienced by others with the installation process and how they were overcome. Further concerns 
relate to the acceptability of the intervention from a staffing perspective, given the potential for 
increased effort required when wheeling objects. We will address this outcome in the review, to try 
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and quantify the extent of the problem, as well as summarise the qualitative findings around these 
issues. Decision-makers will have to balance this risk against the potential benefits for patient 
outcomes, and consider ways the risk to staff can be managed (e.g. through type of equipment in 
use, manual handling policies, staffing levels, area to implement a shock-absorbing floor). We aim 
to present the evidence in such a way as to help decision-makers apply the new knowledge to their 
specific contexts and make an informed choice. 
 
Financing an innovative floor may be a barrier, particularly in situations where the estates and 
facilities budget may be handled separately to budgets used for clinical care (an overspend in one 
budget may lead to savings in another), or where short-term financial pressures outweigh the 
potential long-term gains. Through our review process we will be seeking to engage with 
stakeholders from estates and clinical care, as well as Chief Executives and managers, and we hope 
that by targeting these different areas and levels of influence, we will help generate a shared 
understanding to influence future change.  
 
What do we think the impact of our research will be and for whom?  
The findings of this review will help inform decisions to influence patient benefit (falls and injuries 
prevention in hospitals and care homes), staff wellbeing (injury prevention), care environments 
(flooring choices), all leading to efficiency savings for the NHS in the longer term. The wider 
repercussions of improving inpatient falls/injuries for public wellbeing include: reducing the extent of 
post-discharge formal and informal care requirements and increasing independence. The most direct 
result of this project will be to inform decisions on care environments (depending on the direction of 
results - the uptake or otherwise of shock-absorbing floors). Our Advisory Board and wider 
stakeholder engagement will be integral to helping us realise our ambitions for impact. Through our 
engagement with a working member of the CG161 NICE Guideline on falls in older people18, we 
anticipate that evidence from this review will be incorporated into future updates of the NICE 
Guideline (estimated 2020). Our stakeholder organisations include NHS Property Services Ltd, 
which oversees the refurbishment (and new building works) of 3500 NHS buildings (10% of the NHS 
estate), and the Health Estates and Facilities Management Association, which is made up of 8 
regional branches across England and the membership includes 380 Directors and Senior Managers 
of Estates and Facilities working in the NHS; we hope the results of this review will help inform future 
investment decisions in the NHS estate (from 2020), and more widely into care home and nursing 
homes (communicating through, e.g. the National Care Association, and Registered Nursing Home 
Association). These more immediate effects may mature over time as the innovation becomes 
embedded into practice, and uptake is seen more widely. Should the findings of the review prove 
positive, flooring companies may experience a commercial return on their products, contributing to 
economic growth. From an NHS savings point of view, should shock-absorbing flooring reduce 
injuries and not increase falls or overly effect staffing, the cost of refurbishing a ward could be easily 
balanced against the savings of preventing one hip fracture; further consider that the initial outlay for 
refurbishment is for a product that may remain in situ for 15 years and all the injuries and potential 
litigation proceedings that could be prevented over that time. The potential long-term impacts are 
vast. Should the outcomes of the review prove negative, we hope it will help avoid costly mistaken 
decisions (or help with disinvestment), and for areas of the review with inconclusive findings, we will 
seek to address the gaps through further primary research in the next 5 years and onwards. 
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7. Project / research timetable  
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8. Project management  
This project will be managed from the University of Portsmouth (AD). We will establish collaboration 
agreements with our partners (CL, JR, BK, OO), to facilitate our shared understanding of the project 
and deliverables. We will utilise the software ‘Covidence’ to facilitate collaboration across institutions. 
The project team will meet via teleconference at least once a month, and fortnightly during the more 
intense phase of study selection and data collection. Fortnightly meetings will allow us to resolve 
any disagreements which have arisen from the independent screening, data collection and study 
assessment, as well as establishing targets to ensure project timescales are met. We also anticipate 
at least one physical meeting between the researchers at Portsmouth and the health economist in 
Southampton, to discuss the quality, findings, and synthesis of the economic studies.  
 
Public involvement meetings, and wider stakeholder engagement, will be co-ordinated by KFS, who 
will ensure there is independent representation of public opinions at each key stage in the review 
process. Advisory panel meetings (which will also include a public representative) will take place 
every three to four months (four times over project period), to monitor progress and help resolve any 
issues. Team meetings and Advisory Panel meetings will take place via Go-To-Meeting due to 
geographic dispersion, and dates will be scheduled from the start of the project. Public involvement 
meetings will take place in person at the University of Portsmouth. We will regularly communicate 
with all collaborators via email, to summarise key decisions made in meetings, update on progress, 
and ensure everyone understands the next steps. Draft publications will be shared with all 
collaborators via Google Docs to enable individuals to make simultaneous contributions whilst 
maintaining version control. 
 
9. Ethics  
We do not need to obtain ethical review, as this is an evidence synthesis. Nonetheless, our ethical 
considerations102 will relate to: (1) appropriateness of authorship on the final works; (2) avoidance of 
duplication in the publication of the findings – we will be seeking to publish the review in a peer-
reviewed open access journal, and any other media outputs (e.g. blogs, summaries) will be cross-
referenced with the full report; (3) avoiding plagiarism by ensuring that all reported findings are 
sufficiently cited and attributable to the source material; (4) transparency, in the form of 
acknowledging all contributions and competing interests ; (5) having due rigour in the data collection 
and reporting phases of the review (e.g. duplicate screening and extraction, identifying duplicate 
publications) to ensure the accuracy of the findings; and (6) flagging suspected fraudulent or 
plagiarised research to the publishing journals. 
 
10. Patient and Public Involvement  
We held a public involvement meeting on 26th February 2018, with three public members. Our public 
members are all retired, they have personal experience of caring, nursing, falls, hospitals, patient 
and public involvement (PPI) in research, research participation, writing, editing, and involvement in 
filming for educational videos. In this meeting we discussed the draft proposal and PPI over the 
course of the project. As a result, we made changes to our list of secondary outcomes, which settings 
to include in the review, further developed the theoretical framework underpinning the review, and 
discussed how our public members would like to remain engaged during the project (e.g. how many 
meetings, format of the meeting, representation on other meetings). 
 
Specifically, public involvement members emphasised the importance of listing ‘all fractures’ as a 
separate outcome to ‘hip fractures’. It was felt that use of the term ‘peripheral fractures’ was 
confusing, and unclear as to whether it included hip fractures, and since spinal fractures are unlikely 
to be a result of a fall, for any study which measures fall-related injuries, the term ‘fractures’ will 
suitably capture all relevant fractures that may be seen as a result of a fall. The group still felt it 
worthy to consider hip fractures as a separate outcome, due to the associated costs and life-
expectancy associated with this specific event. 
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In discussing the settings to be included in the review, our public involvement members helped refine 
our focus to hospitals and care homes, as the healthcare settings to be included. We discussed the 
idea of other community settings, for example community centres which may be used as venues by 
voluntary sector organisations involved in the delivery of support groups, and GP surgeries. Our 
public involvement members felt that hospitals and care homes (including nursing homes) were the 
most important venues to focus on, as the places that are more likely to be high risk for falls and that 
have physical areas more focussed on caring for the complex health and care needs of older people, 
where compliant flooring could prove a useful investment. Public involvement members also 
highlighted the importance of eyesight, footwear, giddiness (orthostatic hypotension), and stroke, as 
potential modifiers of the relationship between compliant flooring and outcomes. 
 
Our group felt that meeting in person at the University would be beneficial, at regular intervals 
throughout the project, and were receptive to the idea of joining the Advisory Board meetings via 
teleconference in the evenings (to accommodate the time zone variations with our Canadian 
collaborators). One member suggested we use the platform ‘Go-to-Meeting’ as they had experienced 
better reception with this than Skype, when engaging with previous projects. Subsequent to this 
meeting, the draft proposal was circulated to the PPI group who provided feedback on matters of 
clarity and comprehensiveness. Suggestions were made on how to reduce the length of the report, 
and whilst it was felt that the main proposal contained some necessary technical information, 
feedback was provided on the plain language summary, to the point where group members felt the 
plain language summary was easy to read and understand. 
 
Our public and patient involvement group will be involved throughout the project life cycle. They will 
be integral to assuring the transparency and fairness of judgements made throughout the review 
process (in conjunction with risk of bias and GRADE assessments), helping to prioritise outcomes 
and how the findings are set out in Summary of Findings Tables, improving the clarity and the 
appropriate level of comprehensiveness of review outputs, as well as making the findings accessible 
via alternative outputs (including a video involving patient perspectives, and content of the 
Stakeholder Symposium).  
 
We are planning five specific PPI meetings over the course of the project. Each meeting will include 
a brief training session to explain the stage of the review the project is at, and the processes and 
tasks involved. AD/Senior Research Associate will deliver the training. Specific ways in which PPI 
members will be involved at each stage of the review, to coincide with these five meetings include: 
 
1) Commenting on the clarity and comprehensiveness of the protocol (with the opportunity to 
contribute as an author); 
 
2) Providing an independent judgement as to the fairness, transparency, and consistency of risk of 
bias judgements made by the project team; 
 
3) Providing an independent judgement as to the fairness, transparency, and consistency of GRADE 
judgements made by the project team; 
 
4) Informing the Summary of Findings Tables, by commenting on the clarity of the information 
presented, and informing the importance ratings given to outcomes, and the order and presentation 
of comparisons and subgroups listed in the tables. 
 
5) Providing feedback on the clarity, comprehensiveness, and presentation of the project outputs 
(including the Plain English Summary). 
 
In between meetings our PPI members will be given time to review and comment on documents, so 
thoughts that occur to members after the physical meeting can be fed back to the team. Additionally 
our PPI members will be involved in the creation of a video, where they will help translate the key 
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messages from the review into stories from a patient perspective. This will involve at least two 
additional meetings, electronic exchanges, and a day for the set-up and filming. They will also be 
involved in the planning of the Stakeholder Symposium and are likely to be involved in presenting 
some information at this event, such as the importance of the research from a public perspective, 
and helping to facilitate some of the discussions by for example, taking key notes. 
 
Supplementary to these meetings, our PPI members will have positions on the Advisory Board. We 
will aim to have at least one or more members of the PPI team at these meetings, which will take 
place in the evening via teleconference. Members in need of additional support to join these 
meetings will be welcome to physically meet with the lead applicant (AD) so they can call in together. 
 
Our PPI members will be appropriately compensated and recognised for their time in the project via 
payments, authorship, and acknowledgements. All of our PPI members have access to a computer, 
however they will be given the option to receive documents in hard or electronic copy, and any 
printing will be covered by the University of Portsmouth. 
 
Our PPI members all support the involvement plan. There may be unforeseen times when not every 
member will be available to provide input into a specific activity. Our aim is to ensure we have one 
or more PPI members contribute in each of the ways we have outlined, but with no obligation on any 
one person to contribute at any one time. We feel our PPI team is large enough to meet this aim, but 
we will recruit additional members if required. 
 
11. Project / research expertise  
Lambert Felix has been recruited as a Senior Research Associate. He is a Chartered 
Physiotherapist, and currently undertaking a postgraduate diploma in health economics and health 
policy at the University of Birmingham. LF has more than 11 years’ of research experience in 
systematic reviews of healthcare interventions. He worked for a brief period as a Community 
Physiotherapist with the NHS and had an opportunity to support the falls prevention service. He will 
be full-time for the 14 month project period, and will be responsible for the day-to-day running of the 
project.  He will be involved in every aspect of the review, and will screen, extract data from all 
relevant records, undertake data analysis, write the report, and participate in dissemination activities. 
 
Dr. Amy Drahota will oversee the project as Principal Investigator (PI). She is an experienced 
supervisor and PI, has led primary research on shock-absorbing flooring in hospitals, and had 
various roles in Cochrane (author, trainer, methodologist, and consultant), providing a sound 
knowledge-base in systematic reviews. She will supervise the Senior Research Associate, provide 
expertise in systematic review methods and shock-absorbing flooring research (from a health 
sciences perspective), and will undertake key tasks that require doing independently in duplicate, 
contribute to data analyses, the interpretation of findings, and the research outputs. She will be 
contributing 39 days to this project.  
 
Dr. Bethany Keenan (BK), Dr. Chantelle Lachance (CL), and Dr. Olanrewaju Okunribido (OO) will all 
undertake key tasks that require doing independently in duplicate, they will be involved in the data 
collection form development and piloting, and contribute to the interpretation of findings and the 
research outputs. They each will attend team meetings and Advisory Board meetings and be 
contributing 10 days to the project. 
 
BK provides expertise in biomechanics and materials, to include characterising flooring interventions 
(from an engineering perspective). She has been involved in the development of an international 
standard for shock-absorbency testing and has been working with AD to provide the engineering 
expertise to help characterise and select suitable floors for use in clinical research.  
 
CL provides expertise on systematic reviews, knowledge translation, and shock-absorbing flooring 
research (from a health science perspective). She led on the scoping review which forms the 
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foundation for this systematic review, and has undertaken primary research in this field. CL has been 
a Postdoctoral Fellow in the Knowledge Synthesis Team at St Michael’s Hospital, Canada, and she 
will be contributing 10 days of her time to this project in kind.  
 
OO is a Senior Ergonomics and Human Factors Specialist providing expertise on manual handling 
injuries during push-pull tasks as well as falls prevention. OO has led on the development of a risk 
assessment tool for staff roles involving push-pull tasks, has undertaken research to help understand 
contributing factors to manual handling injuries, and is involved in accident investigations and 
guidance formation. The Health & Safety Laboratory are contributing 10 days of OOs time to the 
project in kind. 
 
Ms. Kirsten Farrell-Savage is a qualified radiographer (with expertise in fracture diagnostics) and is 
the External Promotion and Liaison Lead for the School of Health Sciences and Social Work, bringing 
experience in public and stakeholder involvement. She will co-ordinate our public involvement and 
stakeholder engagement activities alongside contributing to some of the review processes (study 
selection, data collection, quality assessments) by helping to resolve disagreements, interpret the 
findings, and contribute to the research outputs. She will contribute 15 days to this project. 
 
Prof James Raftery is a health economist, and Professor of Health Technology Assessment (working 
part-time for the University of Southampton). He is a former chair of the NIHR Evaluation Trials and 
Studies Cooodinating Centre (NETSCC) and has led several research projects including an update 
of the literature on assessing the impact of the HTA programme, and assessment of funding 
expenditure in relation to disease burden. He has led the economic elements of an extensive range 
of projects, including in clinical trials, systematic reviews, and the political economy of healthcare. 
He will lead on the methodological aspects of synthesising economic studies, reviewing all of the 
economic studies, collecting data on them, undertaking quality assessments, and informing the 
interpretation and summary of the economic findings. He will contribute six days to this project. 
 
Ms Julie Windsor is a registered nurse by background, and the Patient Safety Clinical Lead - Medical 
Specialties/Older People for NHS Improvement, with a leading role in falls prevention activities 
across England. She sits on the NICE Clinical Guidelines panel for falls prevention in older people, 
and is extensively networked with knowledge users relevant to this review. Her role in the project as 
an Advisory Board member, will be related to shaping the protocol, interpretation of findings, 
contributing to the research outputs, and facilitating the uptake of findings. 
 
Prof. Dawn Mackey (DM) is the Director of the Aging and Population Health Laboratory at Simon 
Fraser University, Canada. She is a PI on a shock-absorbing flooring clinical and cost-effectiveness 
study (FLIP study) currently undergoing analysis45. She secured funding for and supervised the 
scoping review on shock-absorbing flooring1. Her research incorporates techniques from 
epidemiology and biostatistics, including clinical trials, longitudinal cohort studies, knowledge 
synthesis, and meta-analysis, as well as laboratory-based studies. As an Advisory Board member 
she will be involved in providing guidance on designing the protocol, supplying supplementary 
evidence from primary research, interpreting the findings, and contributing to research outputs. 
 
Prof. Andrew Laing is the Director of the Injury Biomechanics and Aging Laboratory at the University 
of Waterloo, Canada, with expertise in musculoskeletal biomechanics related to human health, 
mobility, and injury prevention. His research interests centre on fall-related tissue trauma (including 
hip fractures, spinal cord injuries, and traumatic brain injuries), balance and mobility issues that could 
increase the risk of fall-related injuries, and workplace musculoskeletal disorders. He is a PI on the 
FLIP study45 with DM and involved in the development of an international standard for shock-
absorbency testing with BK. As an Advisory Board member, he will be involved in providing guidance 
on designing the protocol, interpreting the findings, and contributing to research outputs. 
 
Alison Cracknell (AC; Consultant in Medicine for Older People) and Anna Winfield (AW; Speciality 
Doctor Elderly Medicine) from Leeds Teaching Hospitals NHS Trust are further clinical 
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representatives and will be members of our Advisory Board. AC is Associate Medical Director for 
Quality Improvement at Leeds Teaching Hospitals, and Clinical Lead for the Yorkshire and Humber 
Patient Safety Collaborative. She is an active researcher and experienced in patient safety, 
improvement, and implementing innovations into frontline clinical practice. AC, working with AW, led 
the Health Foundation Scaling up Improvement Grant: “Huddle Up for Safer Healthcare”, working 
with >150 frontline teams across three acute Trusts, to combine a huddle with improving patient 
safety and team working. In 2014 AC was named as one of the HSJ (Health Service Journal) Top 
Innovators in Healthcare.  
 
AW is a Specialty Doctor in Elderly Medicine at Leeds Teaching Hospitals, a Clinical Lead for Quality 
Improvement (QI) at the Yorkshire and Humber AHSN Improvement Academy and Clinical Tutor for 
Speciality and Associate Specialist (SAS) doctors across the Trust. She is extremely passionate 
about leading frontline teams in QI and improving patient safety. One of her major interests is 
inpatient falls and she is the Clinical Lead for the 'Falls QI Collaborative' at Leeds Teaching 
Hospitals. Alongside her colleague, she was ‘runner up’ for the NHS Improvement Sir Peter Carr 
Award. She has led multiple QI work and is experienced in embedding evidence based innovations 
into clinical practice. As Advisory Board members, AC and AW will be involved in providing guidance 
on designing the protocol, interpreting the findings, and contributing to research outputs. 
 
Mrs. Margaret Bell, Ms Joleen Tobias, and Ms. Liz Burden are public involvement members, 
contributing as described in the PPI section above. 
 
Mr Jonathan Stewart (JS) is the National Chairman for the Health Estates and Facilities Management 
Association (HEFMA), and Director of HEFMA Ltd., and is highly experienced as an independent 
estates and facilities management consultant.  HEFMA represents many of the Estates and Facilities 
professionals working within the NHS. JS can provide access to the HEFMA membership for the 
purposes of our stakeholder engagement plan and for disseminating research findings. JS will also 
facilitate dissemination via the HEFMA magazine, which has wide readership across the health 
sector and suppliers. JS will be an Advisory Board member, providing guidance on interpreting the 
findings, contributing to research outputs, and facilitating the uptake of findings into practice. 
 
Nadra Ahmed (NA), who received an OBE in 2006 for services to social care, has been Chairman 
of the National Care Association since 2001. She has been involved in the field of social care for 
over 35 years and until 2005 was the Registered Manager of two private care homes for older people, 
having developed and run services since 1981. NA has served on numerous government task forces 
and she was the Vice Chairman of Skills for Care for 11 years. NA is a trustee of Parkinson's UK 
among other charities, the Deputy Lord Lieutenant of Kent and a Kent Ambassador. She is a regular 
contributor to journals and speaks at national and international conferences. She is also regularly 
called upon by the major media networks to represent the views of social care providers. NA is driven 
by a desire to ensure the delivery of quality services to the most vulnerable members of our society. 
She works across a number of government departments which have an impact on the social care 
world giving evidence and expert advice to parliamentarians. NA will be an Advisory Board member, 
representing the views of social care providers, providing guidance on interpreting the findings, 
contributing to research outputs, and facilitating the uptake of findings into practice via her networks. 
 
12. Success criteria and barriers to proposed work  
Our success criteria are aligned to our ten project outputs (described above) and project schedule. 
More so than submitting timely articles and creating the outputs by the end of the project period, we 
wish to document the interest and where possible the uptake of the findings to demonstrate tangible 
impacts. This measurement, will by necessity, extend beyond the end of the grant funding period. 
We plan to establish mechanisms which will support our ongoing engagement with potential 
knowledge users, by maintaining a secure database of their contact details (established over the 
course of the project period, which includes their communication preferences). We will use this 
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information to keep our stakeholders updated of our progress in this field, extending beyond the 
period of the project grant, and to continue to invite feedback from them to keep us abreast of any 
actions people are taking on the basis of the review findings. 
 
Risks to the project include running over schedule and lack of cohesion of the project team. We will 
mitigate against these risks through regular virtual meetings to keep us on track and maintain an 
open dialogue. Alongside considering the estimated size of our review, we have taken time to 
develop a realistic project schedule, which takes into consideration the steps involved in the 
systematic review process, which can take time regardless of the number of studies included. Our 
collaborative team, includes leading international researchers in the field, and through this review, 
we will be building upon our working relationships and joint track-record, which we envisage will lead 
to stronger, future interdisciplinary bids, to address some of the challenges facing the field. All 
members of the team are ambitious and keen to make this project a success, as demonstrated 
through the offers of people’s time we have had approved (10 days of CL, 10 days of OO), and time 
offered by our Advisory Board members in kind. 
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Appendix A: Medline search, accessed via EBSCO 
 
1 MH "Wounds and Injuries+ 
2 MH "Accidental Falls/PC” 
3 MH "Hip Fractures+/PC" 
4 fall$ 
5 faller$ 
6 S1 OR S2 OR S3 OR S4 OR S5 
7 MH "Aged+" 
8 MH "Middle Aged" 
9 Older 
10 Senior$ 
11 elderly 
12 S7 OR S8 OR S9 OR S10 OR S11 
13 S6 AND S12 
14 MH "Residential Facilities+" 
15 MH "Long-Term Care" 
16 MH "Institutionalization" 
17 MH "Hospitalization" 
18 MH "Subacute Care" 
19 MH "Hospitals+" 
20 MH "Hospital Units" 
21 MH "Rehabilitation Centers" 
22 MH "Inpatients" 
23 MH "Geriatric Assessment" 
24 ("long stay" or "long term" or "acute" or "sub‐acute" or "subacute" or "residential" or "hospital") N3 (care or 
ward# or hospital)  
25 (rehabilitation or geriatric) N1 (ward# or hospital# or unit# or department#)  
26 hostel$ or nursing home$ 
27 inpatient 
28 resident$ 
29 institution$ 
30 S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR 
S26 OR S27 OR S28 OR S29  
31 S13 and S30 
32 floor* NOT (pelvic floor OR sinus OR mouth)  
33 carpet* 
34 ground surface$ 
35 smartcell* 
36 tarkett 
37 softile 
38 sorbashock 
39 forbo 
40 kradal 
41 noraplan 
42 MH "Floors and Floorcoverings" 
43 S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42  
44 S31 AND S43 
45 MH "Animals+" 
46 MH "Humans" 
47 S45 NOT S46 
48 S44 NOT S47 
49 S44 NOT S47  
Limiters - Date of Publication: 2016-05-01- 
 
